October 4th 2022
Healthcare Daily
 

PRDecoded and the Purpose Awards are almost here. Go here to find out more about the panels, agenda and network opportunities.

The newly approved treatment for ALS will cost $158,000 per year, though the maker of the drug, Amylyx Pharmaceuticals, said most patients will pay very little for it themselves. The drug will be marketed under the brand Relyvrio. 

The number of people worldwide with type 1 diabetes could double worldwide by 2040, according to a story published in Lancet Diabetes & Endocrinology. Research has estimated that more than 8 million people live with the disease globally.

Children’s hospitals are stripping information about the services they provide after a string of threats targeting those that provide gender-affirming care, and even those that don’t. Advocates say it could make it more difficult for transgender individuals to get care.

You can still enter the PRWeek Awards U.S. 2023! Go here to find out more.

PRDecoded and Purpose Awards 2022 are heading back to Chicago October 11-12. Go here for the agenda and more information. 

Celebrate PRWeek's 40 Under 40 class of 2022 in-person in Manhattan on October 27. Get your tickets here

Buy the Premium Edition of PRWeek's 2022 Salary Survey here and Communications Bellwether Survey here.

 
 
 
Today's top stories
 
Who is Dairy Milk sponsoring in the New York City Marathon? Every female runner who joins its team
Who is Dairy Milk sponsoring in the New York City Marathon? Every female runner who joins its team
 
The category of MilkPEP will match the registration cost for every woman who signs up in donations to Girls on the Run.
 
Onwards and upwards: Navigating a turbulent market with purpose
Onwards and upwards: Navigating a turbulent market with purpose
 
Now is the time to go on the offense and focus on how you allocate capital to build long-term value, and best communicate that to the financial community, says MacDougall’s Sara Michelmore.
 
Fingerpaint buys med-comms shop Parsons
Fingerpaint buys med-comms shop Parsons
 
The agency’s latest acquisition marks its second in the past three months.
 
 
Partner content
 
Health tech’s post-pandemic pivot: Implications for marketing and communications professionals
Health tech’s post-pandemic pivot: Implications for marketing and communications professionals
 
New research from the Allison+Partners Health practice points to a shift in the health tech landscape that will put increased pressure on marketing and communications professionals to communicate their value more clearly and concisely.
In partnership with
 
Allison+Partners
 
 
 
Bellwether Survey
 
Communications Bellwether Survey 2022: PR in pole position
Communications Bellwether Survey 2022: PR in pole position
 
The fifth collaboration between PRWeek and Boston University portrays an industry that has the ear of the C-suite but faces new expectations to deliver value.
 
 
Health Influencer 30
 
Health Influencer 30: Class of 2021
Health Influencer 30: Class of 2021
 
PRWeek highlights the execs bringing modern communication skills and inspirational leadership to a rapidly transforming healthcare marketplace.
 
 
 
 

© 2022 Haymarket Media Group  |  Terms & Conditions  |  Privacy Notice